Neuroscience With a Clear Purpose
We develop next-generation therapeutics for serious central nervous system conditions where effective treatments remain a critical unmet need. By combining neuroscience research with medicinal chemistry and pharmaceutical development expertise, we aim to translate promising science into practical medicines that improve patients’ lives.


A Pipeline Built Around Unmet Need
Our pipeline includes EQL-101, an ibogaine-inspired preclinical program, and TRH-NP, an intranasal nanoparticle program being developed for potential rapid CNS intervention. Our serotonin-releaser discovery platform supports the exploration of future CNS candidates.
We connect clinical research and medicinal chemistry with the pharmaceutical expertise needed to advance these programs toward clinical development. Each follows its own development pathway, guided by scientific evidence and regulatory requirements.


1
EQL-101
Substance Use Disorders; PTSD
-
EQL-101 is an ibogaine-inspired preclinical program that aims to preserve the therapeutic potential of ibogaine-related pharmacology while reducing cardiac risk and avoiding hallucinogenic effects. The program targets substance use disorders, with PTSD as a potential additional indication. Medicinal chemistry, pharmacology, pharmacokinetics and safety assessment guide its development.

2
EQL-988
Rapid CNS Intervention
-
TRH-NP is an intranasal thyrotropin-releasing hormone nanoparticle program being developed for potential rapid CNS intervention. The program explores nanoparticle-based intranasal delivery as a therapeutic approach. Equulus is evaluating the lead clinical indication and planning the preclinical work required to support a new investigational new drug application.

3
SEROTONIN-RELEASER DISCOVERY PLATFORM
Target Indications Under Evaluation
-
Our discovery portfolio explores serotonin-releasing compounds as a source of potential future CNS candidates. MDMA-inspired and fenfluramine-class approaches remain distinct research directions within the portfolio. Compound-specific pharmacology and safety evaluation will guide candidate selection.

“Our ambition is to translate promising neuroscience into practical medicines that help people recover, restore function and reclaim their lives. We combine clinical research with pharmaceutical development expertise, building the evidence for each program while considering how future treatments can be delivered in everyday care.”
Robert P. Discordia, PhD
Co-Founder, President & Chief Executive Officer

Robert Discordia brings more than 30 years of pharmaceutical and biotechnology experience to Equulus. His expertise spans end-to-end drug development, including deep experience in chemistry, manufacturing and controls (CMC). He has advanced programs from preclinical research through clinical development and commercialization across multiple therapeutic areas. At Equulus, he leads corporate strategy and pharmaceutical development, drawing on this experience to advance the pipeline toward clinical and commercial milestones.

Robert Discordia, PhD
Co-Founder, President &
Chief Executive Officer
Peter Hendricks is a clinical psychologist and the Heersink Endowed Professor in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham. His research focuses on psychedelic-assisted therapies and patient outcomes, including substance use disorders. He has designed and led clinical trials of psychedelic-assisted therapies. At Equulus, he guides clinical research strategy and rigorous, patient-centered trial design, drawing on his leadership of these studies.

Peter Hendricks, PhD
Co-Founder, Director &
Chief Advisor on Clinical Psychology
Bruce Blough is a medicinal chemist with decades of experience in CNS drug discovery. His research at Research Triangle Institute helped establish the serotonin-releaser portfolio under evaluation by Equulus. He brings expertise in structure–activity relationships, scaffold design and intellectual-property strategy. At Equulus, he guides molecular design and candidate selection, helping translate discovery findings into candidates suitable for further development.

Bruce Blough, PhD
CCo-Founder, Director &
Chief Advisor on Medicinal Chemistry
Kevin Murnane is Associate Professor of Pharmacology, Toxicology & Neuroscience and of Psychiatry at LSU Health Shreveport, and Director of Basic Science Research at the Louisiana Addiction Research Center. A specialist in neuropharmacology and neurotoxicology, his research examines addiction and stimulant-induced brain injury. At Equulus, he guides preclinical efficacy models, mechanism assessment and the interpretation of pharmacology and safety findings to inform development decisions.

Kevin Murnane, PhD
Co-Founder & Director, Neuropharmacology & Neurotoxicology
Drew Mouton, Co-Founder, Director and Chief Business Officer of Equulus Therapeutics, brings experience in corporate strategy, business development and capital formation. He has executed licensing transactions and strategic alliances, and structured dilutive and non-dilutive financings to advance development programs. At Equulus, he guides business development and financing strategy, building relationships that support the company’s CNS development priorities.

Drew Mouton, MBA, MGM
Co-Founder & Chief Business Officer


Dr. Richard Shelton
University of Alabama at Birmingham

Dr. Bruce Car
Biohaven Pharmaceuticals, CSO

Dr. John Renger
Principal, Neurtuitive,
Former CSO, Cerevel

Pamela Perry
Former SVP, Cerevel Therapeutics

Dr. Neal Naito
CEO, MVK Pharmaceuticals

Dr. Andrew Riley
Assistant Professor of Pharmaceutical Sciences Medicinal Chemistry & Pharmacognosy at the University of Illinois Chicago

Angela Terhune Hargrove
Co-Founder, CSO at First Coast Research Center
Explore the Equulus Opportunity
Equulus Therapeutics is advancing breakthrough therapeutics for central nervous system (CNS) disorders using a transdiagnostic strategy rooted in disease-driving physiology—guided by an experienced neuroscience team and developed with strategic partners. Open the deck to explore our science, programs, and milestones.

OUR PARTNERS
Investor Relations
ir@hlthcommunications.com
HLTH Communications Inc.
Media Inquiries
pr@hlthcommunications.com
HLTH Communications Inc.












